ResApp just focuses on respiratory and already Epat have the...

ResApp just focuses on respiratory and already Epat have the pain application on its way to commercialisation, whether it is used as an assessing tool or as a monitoring application to assess the improvement in people's health, not to mention an infant application. Either way it's all good and as an investor I'm definitely in the right space which is at the forefront of cutting edge technology for health - placing health assistance in the hand of everyone who has a phone. But what can't be underestimated is the potential of the quality of this board who with their experience, I'm sure, are already thinking way ahead about the greater vision of this company positioned in this new space and that is changing the conventional medical and health system thru new hand held technology. I believe the market will soon appreciate this and see that the pain application, the infant child application is just the start of this medical diagnostic portfolio. Given the company will be fully funded for the next 2 to 3 years I can't see any other entry points other than buying on market now. Therefore the danger is if you sell you may not be able to buy them back. I'm sure the ResApp initial shareholders at 2 cents, who sold at 4, have had their smiles wiped off their face ages ago. I myself am just going to allow the board time to do their thing, and I hate to say it, but I reckon If I allow time for the technical up trend to develop I'll at least get 30 - 40 cents